Literature DB >> 19596256

Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.

Jana Balcárková1, Helena Urbánková, Vlastimil Scudla, Milena Holzerová, Jaroslav Bacovský, Karel Indrák, Marie Jarosová.   

Abstract

Abnormalities of chromosome 1 are among the most frequent chromosomal aberrations in patients with multiple myeloma (MM) and are considered a poor-risk genetic feature. To define the frequency and minimal region of 1q gain, we performed immunophenotyping and fluorescence in situ hybridization, comparative genomic hybridization (CGH), and array-CGH in 30 patients in relapse and progression of MM. Gain of 1q21 was found in 15 patients (50%), and in 14 of them whole-arm gain was found. One of these 14 patients had trisomy of chromosome 1 together with whole arm 1q gain, and two others had segmental duplication together with whole arm 1q gain. Segmental duplication of 1q21.1 approximately q23.1 alone was found in one patient. These results confirmed a high frequency of 1q aberrations and revealed that the vast majority of patients with 1q aberration in relapse and progression of MM display whole arm 1q gain. Finally, we observed that 1q gain is highly associated with number of additional changes.

Entities:  

Mesh:

Year:  2009        PMID: 19596256     DOI: 10.1016/j.cancergencyto.2009.02.020

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Genome-wide copy number analysis in pediatric glioblastoma multiforme.

Authors:  Laura Giunti; Marilena Pantaleo; Iacopo Sardi; Aldesia Provenzano; Alberto Magi; Stefania Cardellicchio; Francesca Castiglione; Lorenzo Tattini; Francesca Novara; Anna Maria Buccoliero; Maurizio de Martino; Lorenzo Genitori; Orsetta Zuffardi; Sabrina Giglio
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

2.  Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Authors:  Xiaoyu Qu; Hongli Li; Rita M Braziel; Verena Passerini; Lisa M Rimsza; Eric D Hsi; John P Leonard; Sonali M Smith; Robert Kridel; Oliver Press; Oliver Weigert; Michael LeBlanc; Jonathan W Friedberg; Min Fang
Journal:  Blood       Date:  2018-11-16       Impact factor: 22.113

3.  Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Authors:  Daniel W Sherbenou; Blake T Aftab; Yang Su; Christopher R Behrens; Arun Wiita; Aaron C Logan; Diego Acosta-Alvear; Byron C Hann; Peter Walter; Marc A Shuman; Xiaobo Wu; John P Atkinson; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  J Clin Invest       Date:  2016-11-14       Impact factor: 14.808

4.  Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy.

Authors:  Fabio Sallustio; Claudia Curci; Antonio Giovanni Solimando; Patrizia Leone; Paola Pontrelli; Loreto Gesualdo; Angelo Vacca; Vito Racanelli; Anna Gallone
Journal:  Cancer Biol Ther       Date:  2021-07-21       Impact factor: 4.875

Review 5.  Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme.

Authors:  Marek Mazurek; Cezary Grochowski; Jakub Litak; Ida Osuchowska; Ryszard Maciejewski; Piotr Kamieniak
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

6.  A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation.

Authors:  Laura Giunti; Martina Da Ros; Veronica De Gregorio; Alberto Magi; Samuela Landini; Benedetta Mazzinghi; Anna Maria Buccoliero; Lorenzo Genitori; Sabrina Giglio; Iacopo Sardi
Journal:  Mol Clin Oncol       Date:  2019-01-02

7.  Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context.

Authors:  Pau Ni Ivyna Bong; Ching Ching Ng; Kah Yuen Lam; Puteri Jamilatul Noor Megat Baharuddin; Kian Meng Chang; Zubaidah Zakaria
Journal:  Mol Cytogenet       Date:  2014-04-01       Impact factor: 2.009

8.  Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.

Authors:  Zachary J Walker; Beau M Idler; Lorraine N Davis; Brett M Stevens; Michael J VanWyngarden; Denis Ohlstrom; Shelby C Bearrows; Andrew Hammes; Clayton A Smith; Craig T Jordan; Tomer M Mark; Peter A Forsberg; Daniel W Sherbenou
Journal:  Clin Cancer Res       Date:  2020-10-27       Impact factor: 13.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.